Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines
The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv adm...
Saved in:
Published in | Biologicals Vol. 50; pp. 100 - 108 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.11.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT. |
---|---|
AbstractList | The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT. The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT. The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT. |
Author | Kamachi, Kazunari Hamaguchi, Isao Furuhata, Keiko Asanuma, Hideki Mizukami, Takuo Momose, Haruka Takai, Mamiko Hiradate, Yuki Sasaki, Eita Ishii, Ken J. |
Author_xml | – sequence: 1 givenname: Eita surname: Sasaki fullname: Sasaki, Eita organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 2 givenname: Haruka surname: Momose fullname: Momose, Haruka organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 3 givenname: Yuki surname: Hiradate fullname: Hiradate, Yuki organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 4 givenname: Keiko surname: Furuhata fullname: Furuhata, Keiko organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 5 givenname: Mamiko surname: Takai fullname: Takai, Mamiko organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 6 givenname: Kazunari surname: Kamachi fullname: Kamachi, Kazunari organization: Department of Bacteriology II, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 7 givenname: Hideki surname: Asanuma fullname: Asanuma, Hideki organization: Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208–0011, Japan – sequence: 8 givenname: Ken J. surname: Ishii fullname: Ishii, Ken J. organization: Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan – sequence: 9 givenname: Takuo surname: Mizukami fullname: Mizukami, Takuo email: tmiz@nih.go.jp organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan – sequence: 10 givenname: Isao surname: Hamaguchi fullname: Hamaguchi, Isao organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28838806$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUtv3CAUha0qVfNo_0JFd93YvRjGmFVVjdKHFKmb7BHGl4iJB1zAoySb_vXiTlJV3TQbuILvHME559WJDx6r6h2FhgLtPuyawYUp3Dijp9S0QEUDfQPAXlRnFOSm7lkLJ-vMNzWFTXdanae0A6CUC_6qOm37nvU9dGfVz8uDnhadXfAkWLLX8RYjuUGPBO_miCmtNzoRTeaQ0WenJ1LOR2eyO-CToEgnXG7DjN4ZksOdMy7fExsicV6vqM44ltlOC_oHTQ7aGOcxva5e2vIJfPO4X1TXny-vt1_rq-9fvm0_XdWGiy7XaKwE0Y4gjUBjWskZY2gGriWnWmBrGQcqO-yGXkMnrdD9gEwMsOFoLbuo3h9t5xh-LJiy2rtkcJq0x7AkVTKEFrik4r8olawt6ZW1oG8f0WXY46jm6Eoe9-op3gLII2BiSCmi_YNQUGuVaqf-qnJ9hlDQq1Jl0X78R1si_V1UjtpNz3LYHh2wBHtwGFUyDr0p5UU0WY3BPcPlF6puxY0 |
CitedBy_id | crossref_primary_10_3389_fimmu_2020_02171 crossref_primary_10_3390_vaccines12060583 crossref_primary_10_1038_s41598_019_52686_5 crossref_primary_10_1080_17425255_2020_1807936 crossref_primary_10_1016_j_vaccine_2018_10_009 |
Cites_doi | 10.1016/j.virusres.2004.02.029 10.1016/j.vaccine.2016.12.036 10.7883/yoken1952.28.37 10.1371/journal.pone.0101835 10.1038/nrmicro979 10.1073/pnas.1319268111 10.1016/j.vaccine.2008.02.031 10.4161/hv.22950 10.1038/4401099a 10.1371/journal.pone.0124392 10.1016/S0140-6736(03)15014-3 10.1016/j.vaccine.2013.02.016 |
ContentType | Journal Article |
Copyright | 2017 International Alliance for Biological Standardization Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2017 International Alliance for Biological Standardization – notice: Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION NPM 7X8 7S9 L.6 |
DOI | 10.1016/j.biologicals.2017.08.003 |
DatabaseName | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | PubMed AGRICOLA MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1095-8320 |
EndPage | 108 |
ExternalDocumentID | 28838806 10_1016_j_biologicals_2017_08_003 S1045105617300982 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5VS 6J9 7-5 71M 8P~ 9JM AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMG HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR LG5 LUGTX LZ5 M29 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SES SEW SIN SPCBC SSH SSI SSU SSZ T5K UNMZH WUQ XPP ZMT ~G- ~KM AAHBH AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS NPM 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c476t-ecf9072d09c7ecc294333ecb4a941a7e2f340196e6b8a069f7a8be37b054eff3 |
IEDL.DBID | .~1 |
ISSN | 1045-1056 1095-8320 |
IngestDate | Thu Jul 10 20:07:20 EDT 2025 Fri Jul 11 06:52:54 EDT 2025 Mon Jul 21 05:57:43 EDT 2025 Thu Apr 24 23:03:50 EDT 2025 Tue Jul 01 03:56:50 EDT 2025 Fri Feb 23 02:34:24 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | ATT LTT JMR SA RE WBC Safety test QGP HAv WPV Influenza vaccine Leukopenic toxicity test Marker gene |
Language | English |
License | Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c476t-ecf9072d09c7ecc294333ecb4a941a7e2f340196e6b8a069f7a8be37b054eff3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 28838806 |
PQID | 1932838932 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2010204917 proquest_miscellaneous_1932838932 pubmed_primary_28838806 crossref_primary_10_1016_j_biologicals_2017_08_003 crossref_citationtrail_10_1016_j_biologicals_2017_08_003 elsevier_sciencedirect_doi_10_1016_j_biologicals_2017_08_003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2017 2017-11-00 2017-Nov 20171101 |
PublicationDateYYYYMMDD | 2017-11-01 |
PublicationDate_xml | – month: 11 year: 2017 text: November 2017 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Biologicals |
PublicationTitleAlternate | Biologicals |
PublicationYear | 2017 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | National Institute of Infectious Diseases (bib1) 2006 Mizukami, Imai, Hamaguchi, Kawamura, Momose, Naito (bib3) 2008; 24 Kurokawa, Ishida, Asakawa, Iwasa, Goto (bib2) 1975; 1 Mizukami, Momose, Kuramitsu, Takizawa, Araki, Furuhata (bib5) 2014; 9 Stephenson, Nicholson, Glück, Mischler, Newman, Palache (bib9) 2003; 362 Ato, Takahashi, Fujii, Hashimoto, Kaji, Itamura (bib14) 2013; 31 Kobiyama, Aoshi, Narita, Kuroda, Hayashi, Tetsutani (bib7) 2014; 111 Wood, Robertson (bib12) 2004; 2 Dennis (bib13) 2006; 440 Momose, Mizukami, Kuramitsu, Takizawa, Masumi, Araki (bib6) 2015; 10 Tougan, Aoshi, Coban, Katakai, Kai, Yasutomi (bib8) 2013; 9 WHO (bib11) Hehme, Engelmann, Kuenzel, Neumeier, Saenger (bib10) 2004; 103 Sasaki, Kuramitsu, Momose, Kobiyama, Aoshi, Yamada (bib4) 2017; 35 Momose (10.1016/j.biologicals.2017.08.003_bib6) 2015; 10 Mizukami (10.1016/j.biologicals.2017.08.003_bib5) 2014; 9 National Institute of Infectious Diseases (10.1016/j.biologicals.2017.08.003_bib1) 2006 Dennis (10.1016/j.biologicals.2017.08.003_bib13) 2006; 440 Sasaki (10.1016/j.biologicals.2017.08.003_bib4) 2017; 35 Tougan (10.1016/j.biologicals.2017.08.003_bib8) 2013; 9 Mizukami (10.1016/j.biologicals.2017.08.003_bib3) 2008; 24 Kurokawa (10.1016/j.biologicals.2017.08.003_bib2) 1975; 1 Hehme (10.1016/j.biologicals.2017.08.003_bib10) 2004; 103 Wood (10.1016/j.biologicals.2017.08.003_bib12) 2004; 2 Ato (10.1016/j.biologicals.2017.08.003_bib14) 2013; 31 Kobiyama (10.1016/j.biologicals.2017.08.003_bib7) 2014; 111 WHO (10.1016/j.biologicals.2017.08.003_bib11) Stephenson (10.1016/j.biologicals.2017.08.003_bib9) 2003; 362 |
References_xml | – volume: 111 start-page: 3086 year: 2014 end-page: 3091 ident: bib7 article-title: Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist publication-title: Proc Natl Acad Sci U. S. A – volume: 9 start-page: 283 year: 2013 end-page: 290 ident: bib8 article-title: TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models publication-title: Hum Vaccin Immunother – year: 2006 ident: bib1 article-title: Minimum requirements for biological products – volume: 2 start-page: 842 year: 2004 end-page: 847 ident: bib12 article-title: From lethal virus to life-saving vaccine development inactivated vaccines for pandemic influenza publication-title: Nat Rev Microb – volume: 1 start-page: 37 year: 1975 end-page: 52 ident: bib2 article-title: Toxicities of influenza vaccine: peripheral leukocytic response to live and inactivated influenza viruses in mice publication-title: Jpn J Med Sci Biol – volume: 9 start-page: e101835 year: 2014 ident: bib5 article-title: System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test publication-title: PLoS One – volume: 10 start-page: e0124392 year: 2015 ident: bib6 article-title: Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling publication-title: PLoS One – volume: 24 start-page: 2270 year: 2008 end-page: 2283 ident: bib3 article-title: Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation publication-title: Vaccine – volume: 362 start-page: 1959 year: 2003 end-page: 1966 ident: bib9 article-title: Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial publication-title: Lancet – volume: 31 start-page: 2184 year: 2013 end-page: 2190 ident: bib14 article-title: Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis publication-title: Vaccine – volume: 103 start-page: 163 year: 2004 end-page: 171 ident: bib10 article-title: Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use publication-title: Virus Res – volume: 440 start-page: 1099 year: 2006 ident: bib13 article-title: Flu-vaccine makers toil to boost supply publication-title: Nature – volume: 35 start-page: 821 year: 2017 end-page: 830 ident: bib4 article-title: A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests publication-title: Vaccine – ident: bib11 article-title: Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines – year: 2006 ident: 10.1016/j.biologicals.2017.08.003_bib1 – ident: 10.1016/j.biologicals.2017.08.003_bib11 – volume: 103 start-page: 163 year: 2004 ident: 10.1016/j.biologicals.2017.08.003_bib10 article-title: Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use publication-title: Virus Res doi: 10.1016/j.virusres.2004.02.029 – volume: 35 start-page: 821 year: 2017 ident: 10.1016/j.biologicals.2017.08.003_bib4 article-title: A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests publication-title: Vaccine doi: 10.1016/j.vaccine.2016.12.036 – volume: 1 start-page: 37 year: 1975 ident: 10.1016/j.biologicals.2017.08.003_bib2 article-title: Toxicities of influenza vaccine: peripheral leukocytic response to live and inactivated influenza viruses in mice publication-title: Jpn J Med Sci Biol doi: 10.7883/yoken1952.28.37 – volume: 9 start-page: e101835 year: 2014 ident: 10.1016/j.biologicals.2017.08.003_bib5 article-title: System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test publication-title: PLoS One doi: 10.1371/journal.pone.0101835 – volume: 2 start-page: 842 year: 2004 ident: 10.1016/j.biologicals.2017.08.003_bib12 article-title: From lethal virus to life-saving vaccine development inactivated vaccines for pandemic influenza publication-title: Nat Rev Microb doi: 10.1038/nrmicro979 – volume: 111 start-page: 3086 year: 2014 ident: 10.1016/j.biologicals.2017.08.003_bib7 article-title: Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist publication-title: Proc Natl Acad Sci U. S. A doi: 10.1073/pnas.1319268111 – volume: 24 start-page: 2270 year: 2008 ident: 10.1016/j.biologicals.2017.08.003_bib3 article-title: Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation publication-title: Vaccine doi: 10.1016/j.vaccine.2008.02.031 – volume: 9 start-page: 283 year: 2013 ident: 10.1016/j.biologicals.2017.08.003_bib8 article-title: TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models publication-title: Hum Vaccin Immunother doi: 10.4161/hv.22950 – volume: 440 start-page: 1099 year: 2006 ident: 10.1016/j.biologicals.2017.08.003_bib13 article-title: Flu-vaccine makers toil to boost supply publication-title: Nature doi: 10.1038/4401099a – volume: 10 start-page: e0124392 year: 2015 ident: 10.1016/j.biologicals.2017.08.003_bib6 article-title: Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling publication-title: PLoS One doi: 10.1371/journal.pone.0124392 – volume: 362 start-page: 1959 year: 2003 ident: 10.1016/j.biologicals.2017.08.003_bib9 article-title: Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(03)15014-3 – volume: 31 start-page: 2184 year: 2013 ident: 10.1016/j.biologicals.2017.08.003_bib14 article-title: Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis publication-title: Vaccine doi: 10.1016/j.vaccine.2013.02.016 |
SSID | ssj0011474 |
Score | 2.1535704 |
Snippet | The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 100 |
SubjectTerms | biomarkers gene expression genes genetic markers hemagglutinins influenza Influenza vaccine influenza vaccines leukocytes Leukopenic toxicity test Marker gene mice prediction regression analysis Safety test toxicity toxicity testing |
Title | Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines |
URI | https://dx.doi.org/10.1016/j.biologicals.2017.08.003 https://www.ncbi.nlm.nih.gov/pubmed/28838806 https://www.proquest.com/docview/1932838932 https://www.proquest.com/docview/2010204917 |
Volume | 50 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB_E48SX4z7U2_uQCL7WbZNs28C9yKLsfShyKvgW0jSBqtcublfUh7t__Wb6sZ4cguBT25ApYWYy-YVMfgOwLcwoj11KM82MAokLQKAy54MwV4mztKFoTkwPDuPJqfx2NjpbgnF_F4bSKrvY38b0Jlp3LcNOm8NpUQyPI6JGIQBMlOsqpTgsZUJevvN7keaBcL9hYqbOAfVega37HK-W6Ii0QczdUdKwefb1s_5fox7DoM1atP8aXnUgku2243wDS658Cy_bspK37-DP3oLCm1We_aIMnCuGnuKYu-kSX0tmZsywaVVTuhD-DNvzogl-vQCKXrr5BdXXKiyrq5vCImRniHJZUdJ9iGvEqTm-N2VO7gy7NpaO6WdrcLK_dzKeBF2hhcCiwurAWY97ZJ6HyqKBLFdSCOFsJo2SkUkc90ISj46Ls9SEsfKJSTMnkgzxnvNerMNyWZXuPbBMWakiy72PrJR5aizPeZiNhLUiDpN8AGmvWW07EnKqhXGp-2yzc_2PUTQZRVOdzFAMgC9Epy0Tx1OEvvTm0w_cSuOK8RTxrd7kGqcdnaWY0lXzmSbcmxLY44_3oUQDjjuwKBnARusvi5FTkWcMnfGH5w3wI6zSV3s58hMs11dz9xlRUp1tNtNgE17sjn_-OKLn1--Tw78bXxfZ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7Chia9lLZJ2u1TgVzN2pL8EPQSQsKmSfaSDeQmZFkCt6m9ZL0h7aV_vTN-bFtKINCbsTVGaKTRJ2b0fQAHwsRF4jJaaSYOJG4AgcqdD8JCpc7SgaLNmF7MkumV_HwdX2_A0XAXhsoq-9jfxfQ2WvdvJv1oThZlObmMiBqFADBRrqsM4_AmsVPFI9g8PD2bztbJhEi2ZMzUPiCDLdj_XebVcR3RgBB5d5S2hJ6DhNa_29RDMLTdjk6ew7MeR7LDrqsvYMNVL-FJpyz5fQd-Hq9ZvFnt2TcqwrllOFkcc_d97WvFzJIZtqgbqhjCn-H7omzj32CApjdu9ZUktkrLmvq-tIjaGQJdVlZ0JeIOoWqBz63SyQ_D7oylTP1yF-Ynx_OjadBrLQRWpkkTOOvxmMyLUFn0keVKCiGczaVRMjKp415IotJxSZ6ZMFE-NVnuRJoj5HPeiz0YVXXlXgPLlZUqstz7yEpZZMbygod5LKwVSZgWY8iGkdW25yEnOYwbPRScfdF_OEWTUzRJZYZiDHxtuujIOB5j9Glwn_5rZmncNB5jvj-4XOPKo3SKqVy9WmqCvhnhPf5wG6o14HgIi9IxvOrmy7rnpPOM0TN5838d_Ajb0_nFuT4_nZ29haf0pbsr-Q5Gze3KvUfQ1OQf-kXxC9EeGPU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+marker+gene+expression+as+a+potential+predictive+marker+of+leukopenic+toxicity+for+inactivated+influenza+vaccines&rft.jtitle=Biologicals&rft.au=Sasaki%2C+Eita&rft.au=Momose%2C+Haruka&rft.au=Hiradate%2C+Yuki&rft.au=Furuhata%2C+Keiko&rft.date=2017-11-01&rft.eissn=1095-8320&rft.volume=50&rft.spage=100&rft_id=info:doi/10.1016%2Fj.biologicals.2017.08.003&rft_id=info%3Apmid%2F28838806&rft.externalDocID=28838806 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-1056&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-1056&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-1056&client=summon |